Skip to main content
SpringerLink
Log in

Dopamine Resistance of Prolactinomas

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Resistance to dopamine agonists can be defined with respect to failure to normalize PRL levels and failure to decrease tumor size by ≥50%. Using these definitions, failure to normalize PRL levels is seen in 24% of those treated with bromocriptine, 13% of those treated with pergolide and 11% of those treated with cabergoline. Failure to achieve at least a 50% reduction in tumor size occurs in about one-third of those treated with bromocriptine and 10–15% of those treated with pergolide or cabergoline. Studies of in vitro cell preparations show that the D2 receptors of resistant tumors are decreased in number but have normal affinity.

Treatment approaches for resistant patients include switching to another dopamine agonist and raising the dose of the drug as long as there is continued response to the dose increases and no adverse effects. Transsphenoidal surgery can also be done. If fertility is desired, clomiphene, gonadotropins, and GnRH are also options. If fertility is not desired, estrogen replacement may be used unless there is a macroadenoma, in which case control of tumor growth is also an issue and dopamine agonists are generally necessary. However, in many cases modest or even no reduction may be acceptable long-term as long as there is not tumor growth. Hormone replacement (estrogen or testosterone) may cause a decrease in efficacy of the dopamine agonist so that it must be carried out cautiously. Reduction of endogenous estrogen, use of selective estrogen receptor modulators, and aromatase inhibitors are potential experimental approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin N Amer 2001;30:585–610.

    Google Scholar 

  2. Soule SG, Powell M, Jacobs HS. Prolactinomas resistant to dopamine agonists: Insights into pathogenesis and therapy. Curr Opin Obstet Gynecol 1994;6:393–397.

    Google Scholar 

  3. Monsma FJ Jr, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 1989;342:926–929.

    Google Scholar 

  4. DeCamilli P, Macconi D, Spada A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 1979;278:252–254.

    Google Scholar 

  5. Senogles SE. The D2 dopamine receptor isoforms signal through distinct Gia proteins to inhibit adenylyl cyclase. J Biol Chem 1994;269:23120–23127.

    Google Scholar 

  6. Rasolonjanahary R, Gerard C, Dufour MN, Homburger V, Enjalbert A, Guillon G. Evidence for a direct negative coupling between dopamine-D2 receptors and PLC by heterotrimeric Gi1/2 proteins in rat anterior pituitary cell membranes. Endocrinology 2002:143:747–754.

    Google Scholar 

  7. Vallar L, Vicentini LM, Meldolesi J. Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem 1988;263:10127–10134.

    Google Scholar 

  8. Liu JC, Baker RE, Sun C, Sundmark VC, Elsholtz HP. Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene. J Biol Chem 2002;277:35819–35825.

    Google Scholar 

  9. Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R, Borrelli E. Control of lactotroph proliferation by dopamine: Essential role of signaling through D2 receptors and ERKS. PNAS 2002;99:14530–14535.

    Google Scholar 

  10. Tindall GT, Kovacs Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactin-producing adenomas and bromocriptine: A histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982;55:1178–1183.

    Google Scholar 

  11. Bassetti M, Spada A, Pezzo G, Giannattasio G. Bromocriptine treatment reduces the cell size in human macroprolactinomas: A morphometric study. J Clin Endocrinol Metab 1984;58:268–273.

    Google Scholar 

  12. Stefaneanu L, Kovacs K, Scheithauer BW, Konogeorgos G, Riehle DL, Sebo TJ, Murray D, Vidal S, Tran A, Buchfelder M, Fahlbusch R. Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocrine Pathol 2000;11:341–352.

    Google Scholar 

  13. Aoki MDP, Aoki A, Maldonado CA. Sexual dimorphism of apoptosis in lactotrophs induced by bromocryptine. Histochem Cell Biol 2001;116:215–222.

    Google Scholar 

  14. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500–509.

    Google Scholar 

  15. Brue T, Pellegrini I, Gunz G, Morange I, DeWailly D, Brownell J, Enjalbert A, Jaquet P. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74:577–584.

    Google Scholar 

  16. Delgrange E, Maiter D, Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinomas intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454–456.

    Google Scholar 

  17. DiSarno A, Landi ML, Cappabianca P, DiSalle F, Rossi FW, Pivonello R, DiSomma C, Faggiano A, Lombardi G, Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86:5256–5261.

    Google Scholar 

  18. Cannavó S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 1999;22:306–309.

    Google Scholar 

  19. Delgrange E, Crabbé J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 1998;49:250–253.

    Google Scholar 

  20. Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH. Metastatic prolactinoma: Effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 1997;2962–2965.

  21. Fossati P, Strauch G, Tournaiaire J. Etude de l'activité de la bromocriptine dans les états d'hyperprolactinémie. Nouv Presse Med 1976;5:1687–1691.

    Google Scholar 

  22. Friesen HG, Tolis G. The use of bromocriptine in the galactorrhoea-amenorrhoea syndromes: The Canadian Cooperative Study. Clin Endocrinol 1977;6(Suppl):91s–99s.

    Google Scholar 

  23. Bergh T, Nillius SJ, Wide L. Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol 1978;88:435–451.

    Google Scholar 

  24. Badano AR, Miechi HR, Mirkin A, Arcángeli OA, Aparicio NJ, Rodríguez A, Oliva A, Turner D, Casas PRF. Bromocriptine in the treatment of hyperprolactinemic amenorrhea. Fertil Steril 1979;31:124–128.

    Google Scholar 

  25. Crosignani PG, Ferrari C, Liuzzi A, Benco R, Mattei A, Rampini P, Dellabonanza D, Scarduelli C, Spelta B. Treatment of hyperprolactinemic states with different drugs: A study with bromocriptine, metergoline, and lisuride. Fertil Steril 1982;37:61–67.

    Google Scholar 

  26. Horowitz BL, Hamilton DJ, Sommers CJ, Bryan RN, Boyd AE III. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin. AJNR 1983;4:415–417.

    Google Scholar 

  27. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698–705.

    Google Scholar 

  28. Liuzzi A, Dallabonzana D, Giuseppe MD et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656–659.

    Google Scholar 

  29. Van der Heijden PFM, de Wit W, Brownell J, Schoemaker J, Rolland R. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 1991;40:111–118.

    Google Scholar 

  30. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm Res 1992;38:84–89.

    Google Scholar 

  31. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904–909.

    Google Scholar 

  32. Pascal-Vigneron V, Weryha G, Bose M, Leclere J. Hyperprolactinemic amenorrhea: Treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med 1995;24:754–757.

    Google Scholar 

  33. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro-and macroprolactinomas in men. J Clin Endocrinol Metab 2000;85:3053–3057.

    Google Scholar 

  34. Sabancu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med 2001;40:857–861.

    Google Scholar 

  35. Kleinberg DL, Boyd AE III, Wardlaw S, Frantz AG, George A, Bryan N, Hilal S, Greising J, Hamilton D, Seltzer T, Sommers CJ. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983;309:704–709.

    Google Scholar 

  36. L'Hermite M, Debusschere PM, Gillet C, Deschepper C. Treatment of hyperprolactinaemic patients with pergolide. Acta Endocrinol 1983;103:441–445.

    Google Scholar 

  37. Freda PU, Andreadis CI, Knandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL. Long-term treatment of prolactinsecreting macroadenomas with pergolide. J Clin Endocrinol Metab 2000;85:8–13.

    Google Scholar 

  38. Ferrari C, Mattei A, Melis GB et al. Cabergoline: Long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68:1201–1206.

    Google Scholar 

  39. Ferrari C, Paracchi A, Mattei AM, de Vincentils S, D'Alberton A, Crosignani PG. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;126:489–494.

    Google Scholar 

  40. Muratori M, Arosio M, gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of 26 Molitch hyperprolactinemic and acromegalic patients. J Endocrinol Invest 1997;20:537–546.

    Google Scholar 

  41. Verhelst J, Abs R, Maiter D et al. Cabergoline in the treatment of hyperprolactinemia:Astudy in 455 patients. J Clin Endocrinol Metab 1999;84:2518–2522.

    Google Scholar 

  42. Colao A, DiSarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, DiSalle F, Cirillo S, Annunziato L, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clin Endocrinol Metab 2000;85:2246–2252.

    Google Scholar 

  43. Thorner MO, Schran HF, Evans WS, Rogol AD, Morris JL, MacLeod RM. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J Clin Endocrinol Metab 1980;50:1026–1033.

    Google Scholar 

  44. Burris TP, Stringer LC, Freeman ME. Pharmacologic evidence that a D2 receptor subtype mediates dopaminergic stimulation of prolactin secretion from the anterior pituitary gland. Neuroendocrinology 1991;54:175–183.

    Google Scholar 

  45. Caccavelli L, Feron F, Morange I et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptineresistant prolactinomas. Neuroendocrinol 1994;60:314–322.

    Google Scholar 

  46. Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A. Alteration of Ga subunits mRNA levels in bromocriptine resistant adenomas. J Neuroendocrinol 1996;8:737–746.

    Google Scholar 

  47. Ahmed SR, Shalet SM. Discordant responses of prolactinomas to two different dopamine agonists. Clin Endocrinol 1986;24:421–426.

    Google Scholar 

  48. Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Isr J Med Sci 1991;27:375–379.

    Google Scholar 

  49. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM. Effect of the new dopaminergic agonist CV205-502 on plasma prolactin levels and tumour size in bromocriptineresistant prolactinomas. Clin Endocrinol 1991;34:25–29.

    Google Scholar 

  50. Razzaq R, O'Halloran DJ, Beardwell CG, Shalet SM. The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine. Horm Res 1993;39:218–222.

    Google Scholar 

  51. Merola B, Sarnacchiaro F, Colao A, DiSomma C, DiSarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C, Lombardi G. Positive response to compound CV205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994;8:175–181.

    Google Scholar 

  52. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996;135:413–420.

    Google Scholar 

  53. Rohmer V, Freneau E, Morange I, Simonetta C, and Le Club de l'Hypophyse. Efficiency of quinagolide in resistance to ergotderived dopamine agonists: Results of a multicenter study.Ann Endocrinol 2000;61:411–417.

    Google Scholar 

  54. Colao A, DiSarno A, Sarnacchiaro F, Ferone D, DiRenzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876–883.

    Google Scholar 

  55. Gillam MP, Middler S, Freed DJ, Molitch ME. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 2002;87:4447–4451.

    Google Scholar 

  56. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202–212.

    Google Scholar 

  57. Inzelberg R, Nisipeanu P, Rabey JM, Orlov E, Catz T, Kippervasser S, Schechtman E, Korczyn AD. Doubleblind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785–788.

    Google Scholar 

  58. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Masso JFM, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R, and the PKDS009 Collaborative Study Group. Cabergoline in the treatment of early Parkinson's disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363–368.

    Google Scholar 

  59. Radwanska E, McGarrigle HH, Little V, Lawrence D, Saris S, Swyer GI. Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin or bromocriptine. Fertil Steril 1979;32:187–192.

    Google Scholar 

  60. Crosignani PG, Ferrari C, Scarduelli C, Picciotti MC, Caldara R, Malinverni A. Spontaneous and induced pregnancies in hyperprolactinemic women. Obstet Gynecol 1981;58:708–713.

    Google Scholar 

  61. Leyendecker G, Sruve T, Plotz EJ. Induction of ovulation with chronic intermittent (pulsatile) administration of LH-RH in women with hypothalamic and hyperprolactinemic amenorrhea. Arch Gynecol 1980;229:177–190.

    Google Scholar 

  62. Maurer RA. Estradiol regulates the transcription of the prolactin gene. J Biol Chem 1982;257:2133–2136.

    Google Scholar 

  63. Shull JD, Gorski J. Estrogen regulates the transcription of the rat prolactin gene in vivo through at least two independent mechanisms. Endocrinology 1985;116:2456–2462.

    Google Scholar 

  64. Lloyd GM, Meares JD, Jacobi J. Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 1975;255:497–498.

    Google Scholar 

  65. Raymond V, Beaulieu M, Labrie F, Boissier J. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 1979;200:1173–1175.

    Google Scholar 

  66. West B, Dannies PS. Effects of estradiol on prolactin production and dihydroergocryptine-induced inhibition of prolactin production in primary cultures of rat pituitary cells. Endocrinology 1980;106:1108–1113.

    Google Scholar 

  67. Jaquet P, Gunz G, Grisoli F. Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions. Horm Res 1985;22:153–163.

    Google Scholar 

  68. Heiman ML, Ben-Jonathan N. Rat anterior pituitary dopaminergic receptors are regulated by estradiol during lactation. Endocrinology 1982;111:1057–1060.

    Google Scholar 

  69. Pasqualini C, Bojda F, Kerdelhué B. Direct effect of estradiol on the number of dopamine receptors in the anterior pituitary of ovariectomized rats. Endocrinology 1986;119:2484–2489.

    Google Scholar 

  70. Nansel DD, Gudelsky GA, Reymond MJ, Porter JC. Estrogen alters the responsiveness of the anterior pituitary gland to the actions of dopamine on lysosomal enzyme activity and prolactin release. Endocrinology 1981;108:903–907.

    Google Scholar 

  71. Lamberts SWJ, Verleun T, Hofland L, Oosterom R. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab 1986;63:1342–1347.

    Google Scholar 

  72. Lamberts SWJ. Interactions of steroids with prolactin secretion in vitro. Horm Res 1985;22:172–178.

    Google Scholar 

  73. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993;59:671–673.

    Google Scholar 

  74. Testa G, Vegetti W, Motta T et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 1998;58:69–73.

    Google Scholar 

  75. Fahy UM, Foster PA, Torode HW, Hartog M, Hull MGR. The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. Gynecol Endocrinol 1992;6:183–188.

    Google Scholar 

  76. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS. Prolactinproducing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. Arch Pathol Lab Med 1994;118:562.

    Google Scholar 

  77. Garcia MM, Kapcala LP. Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 1995;18:450–455.

    Google Scholar 

  78. Lamberts SWJ, Verleun T, Oosterom R. Effect of tamoxifen administration on prolactin release by invasive prolactinsecreting pituitary adenomas. Neuroendocrinology 1982;34: 339–342.

    Google Scholar 

  79. Prior JC, Cox TA, Fairholm D, Kostashuk E, Nugent R. Testosterone-related exacerbation of a prolactin-producing macroadenoma: Possible role for estrogen. J Clin Endocrinol Metab 1987;64:391–394.

    Google Scholar 

  80. Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, dal Toso R, Balsari A, Spano PF. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 1993;90:7961–7965.

    Google Scholar 

  81. Missale C, Losa M, Boroni F, Giovanelli M, Balsari A, Spano PF. Nerve growth factor and bromocriptine: A sequential therapy for human bromocriptine-resistant prolactinomas. Brit J Cancer 1995;72:1397–1399.

    Google Scholar 

  82. Fiorentini C, Guerra N, Facchetti M, Finardi A, Tiberio L, Schiaffonati L, Spano P, Missale C. Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via p75NGFR-mediated activation of nuclear factor-κB. Mol Endocrinol 2002;16:353–366.

    Google Scholar 

  83. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Guiliani M, Stevens JC, Barbano R, Dyck PJ for the rhNGF Clinical Investigator Group. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. A randomized controlled trial. JAMA 2000;284:2215–2221.

    Google Scholar 

  84. Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koralnik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McArthur JC, and the AIDS Clinical Trials Group Team 291. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001;57:1313–1316.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA

    Mark E. Molitch (Professor of Medicine)

Authors
  1. Mark E. Molitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molitch, M.E. Dopamine Resistance of Prolactinomas. Pituitary 6, 19–27 (2003). https://doi.org/10.1023/A:1026225625897

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026225625897

Search

Navigation